Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia: Short-term experience with prostcare

Yuh Shyan Tsai, Johnny S.N. Lin, Yat Ching Tong, Tzong Shin Tzai, Wen Horng Yang, Chien Cheng Chang, Hong Lin Cheng, Yung Ming Lin, Yeong Chin Jou

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To assess our short-term experience with transurethral microwave thermotherapy (TUMT) for symptomatic benign prostatic hyperplasia (BPH). Patients and Methods: From August 1993 through July 1994, in total 65 patients with symptomatic BPH were enrolled into this study. The patients' ages ranged from 56 to 95 years with a mean of 70 years. Under local anesthesia with intraurethral instillation of Xylocaine jelly only, all patients received one session of TUMT for up to 60 min with Prostcare equipment. Uroflowmetry was performed and international prostatic symptom score (IPSS) determined before 3 and 6 months after TUMT for assessment of efficacy. All adverse events were recorded and evaluated for clinical relevance. Results: At 3 and 6 months following TUMT, the mean IPSS decreased from 19.7 ± 6.8 (baseline) to 12.8 ± 8.2 (-46%) and to 15.5 ± 9.0 (-21%), respectively; the maximal urine flow rate at 3 and 6 months increased from 9.1 ± 4.8 ml/s (baseline) to 11.0 ± 4.9 ml/s (+21%) and to 10.9 ± 5.6 ml/s (+19%), respectively. During TUMT, burning sensation was the most frequent complaint (38.5%), followed by urethral discomfort (29.2%) and urgency (9.2%). Two patients (3.1%) interrupted TUMT, because of intolerable pain. Following TUMT micturition pain (73.8%) and gross hematuria (45.9%) were the most adverse events. Most of these adverse events disappeared within 2 weeks. One patient suffered from skin erosion over the penoscrotal junction 1 week later. None had retrograde ejaculation; 1 patient complained of erectile dysfunction. Conclusion: Although the efficacy of TUMT with Prostcare became less prominent 6 months after TUMT, TUMT was still a tolerable, safe alternative treatment of BPH, especially in patients who were not suitable for transurethral resection of the prostate or anesthesia. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)89-94
Number of pages6
JournalUrologia Internationalis
Volume65
Issue number2
DOIs
Publication statusPublished - 2000 Jan 1

Fingerprint

Transurethral Resection of Prostate
Prostatic Hyperplasia
Pain
Ejaculation
Urination
Hematuria
Erectile Dysfunction
Local Anesthesia
Lidocaine
Anesthesia
Urine

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

@article{e9916cc44882464e8e57ffa72fb7a586,
title = "Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia: Short-term experience with prostcare",
abstract = "Purpose: To assess our short-term experience with transurethral microwave thermotherapy (TUMT) for symptomatic benign prostatic hyperplasia (BPH). Patients and Methods: From August 1993 through July 1994, in total 65 patients with symptomatic BPH were enrolled into this study. The patients' ages ranged from 56 to 95 years with a mean of 70 years. Under local anesthesia with intraurethral instillation of Xylocaine jelly only, all patients received one session of TUMT for up to 60 min with Prostcare equipment. Uroflowmetry was performed and international prostatic symptom score (IPSS) determined before 3 and 6 months after TUMT for assessment of efficacy. All adverse events were recorded and evaluated for clinical relevance. Results: At 3 and 6 months following TUMT, the mean IPSS decreased from 19.7 ± 6.8 (baseline) to 12.8 ± 8.2 (-46{\%}) and to 15.5 ± 9.0 (-21{\%}), respectively; the maximal urine flow rate at 3 and 6 months increased from 9.1 ± 4.8 ml/s (baseline) to 11.0 ± 4.9 ml/s (+21{\%}) and to 10.9 ± 5.6 ml/s (+19{\%}), respectively. During TUMT, burning sensation was the most frequent complaint (38.5{\%}), followed by urethral discomfort (29.2{\%}) and urgency (9.2{\%}). Two patients (3.1{\%}) interrupted TUMT, because of intolerable pain. Following TUMT micturition pain (73.8{\%}) and gross hematuria (45.9{\%}) were the most adverse events. Most of these adverse events disappeared within 2 weeks. One patient suffered from skin erosion over the penoscrotal junction 1 week later. None had retrograde ejaculation; 1 patient complained of erectile dysfunction. Conclusion: Although the efficacy of TUMT with Prostcare became less prominent 6 months after TUMT, TUMT was still a tolerable, safe alternative treatment of BPH, especially in patients who were not suitable for transurethral resection of the prostate or anesthesia. Copyright (C) 2000 S. Karger AG, Basel.",
author = "Tsai, {Yuh Shyan} and Lin, {Johnny S.N.} and Tong, {Yat Ching} and Tzai, {Tzong Shin} and Yang, {Wen Horng} and Chang, {Chien Cheng} and Cheng, {Hong Lin} and Lin, {Yung Ming} and Jou, {Yeong Chin}",
year = "2000",
month = "1",
day = "1",
doi = "10.1159/000064846",
language = "English",
volume = "65",
pages = "89--94",
journal = "Urologia Internationalis",
issn = "0042-1138",
publisher = "S. Karger AG",
number = "2",

}

Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia : Short-term experience with prostcare. / Tsai, Yuh Shyan; Lin, Johnny S.N.; Tong, Yat Ching; Tzai, Tzong Shin; Yang, Wen Horng; Chang, Chien Cheng; Cheng, Hong Lin; Lin, Yung Ming; Jou, Yeong Chin.

In: Urologia Internationalis, Vol. 65, No. 2, 01.01.2000, p. 89-94.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia

T2 - Short-term experience with prostcare

AU - Tsai, Yuh Shyan

AU - Lin, Johnny S.N.

AU - Tong, Yat Ching

AU - Tzai, Tzong Shin

AU - Yang, Wen Horng

AU - Chang, Chien Cheng

AU - Cheng, Hong Lin

AU - Lin, Yung Ming

AU - Jou, Yeong Chin

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Purpose: To assess our short-term experience with transurethral microwave thermotherapy (TUMT) for symptomatic benign prostatic hyperplasia (BPH). Patients and Methods: From August 1993 through July 1994, in total 65 patients with symptomatic BPH were enrolled into this study. The patients' ages ranged from 56 to 95 years with a mean of 70 years. Under local anesthesia with intraurethral instillation of Xylocaine jelly only, all patients received one session of TUMT for up to 60 min with Prostcare equipment. Uroflowmetry was performed and international prostatic symptom score (IPSS) determined before 3 and 6 months after TUMT for assessment of efficacy. All adverse events were recorded and evaluated for clinical relevance. Results: At 3 and 6 months following TUMT, the mean IPSS decreased from 19.7 ± 6.8 (baseline) to 12.8 ± 8.2 (-46%) and to 15.5 ± 9.0 (-21%), respectively; the maximal urine flow rate at 3 and 6 months increased from 9.1 ± 4.8 ml/s (baseline) to 11.0 ± 4.9 ml/s (+21%) and to 10.9 ± 5.6 ml/s (+19%), respectively. During TUMT, burning sensation was the most frequent complaint (38.5%), followed by urethral discomfort (29.2%) and urgency (9.2%). Two patients (3.1%) interrupted TUMT, because of intolerable pain. Following TUMT micturition pain (73.8%) and gross hematuria (45.9%) were the most adverse events. Most of these adverse events disappeared within 2 weeks. One patient suffered from skin erosion over the penoscrotal junction 1 week later. None had retrograde ejaculation; 1 patient complained of erectile dysfunction. Conclusion: Although the efficacy of TUMT with Prostcare became less prominent 6 months after TUMT, TUMT was still a tolerable, safe alternative treatment of BPH, especially in patients who were not suitable for transurethral resection of the prostate or anesthesia. Copyright (C) 2000 S. Karger AG, Basel.

AB - Purpose: To assess our short-term experience with transurethral microwave thermotherapy (TUMT) for symptomatic benign prostatic hyperplasia (BPH). Patients and Methods: From August 1993 through July 1994, in total 65 patients with symptomatic BPH were enrolled into this study. The patients' ages ranged from 56 to 95 years with a mean of 70 years. Under local anesthesia with intraurethral instillation of Xylocaine jelly only, all patients received one session of TUMT for up to 60 min with Prostcare equipment. Uroflowmetry was performed and international prostatic symptom score (IPSS) determined before 3 and 6 months after TUMT for assessment of efficacy. All adverse events were recorded and evaluated for clinical relevance. Results: At 3 and 6 months following TUMT, the mean IPSS decreased from 19.7 ± 6.8 (baseline) to 12.8 ± 8.2 (-46%) and to 15.5 ± 9.0 (-21%), respectively; the maximal urine flow rate at 3 and 6 months increased from 9.1 ± 4.8 ml/s (baseline) to 11.0 ± 4.9 ml/s (+21%) and to 10.9 ± 5.6 ml/s (+19%), respectively. During TUMT, burning sensation was the most frequent complaint (38.5%), followed by urethral discomfort (29.2%) and urgency (9.2%). Two patients (3.1%) interrupted TUMT, because of intolerable pain. Following TUMT micturition pain (73.8%) and gross hematuria (45.9%) were the most adverse events. Most of these adverse events disappeared within 2 weeks. One patient suffered from skin erosion over the penoscrotal junction 1 week later. None had retrograde ejaculation; 1 patient complained of erectile dysfunction. Conclusion: Although the efficacy of TUMT with Prostcare became less prominent 6 months after TUMT, TUMT was still a tolerable, safe alternative treatment of BPH, especially in patients who were not suitable for transurethral resection of the prostate or anesthesia. Copyright (C) 2000 S. Karger AG, Basel.

UR - http://www.scopus.com/inward/record.url?scp=0033766786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033766786&partnerID=8YFLogxK

U2 - 10.1159/000064846

DO - 10.1159/000064846

M3 - Article

C2 - 11025430

AN - SCOPUS:0033766786

VL - 65

SP - 89

EP - 94

JO - Urologia Internationalis

JF - Urologia Internationalis

SN - 0042-1138

IS - 2

ER -